| YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib I Garmendia, MJ Pajares, F Hermida-Prado, D Ajona, C Bértolo, C Sainz, ... American journal of respiratory and critical care medicine 200 (7), 888-899, 2019 | 61 | 2019 |
| PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas M Sanchez-Canteli, R Granda-Díaz, N del Rio-Ibisate, E Allonca, ... Cancer Immunology, Immunotherapy 69, 2089-2100, 2020 | 51 | 2020 |
| SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation E Redin, I Garmendia, T Lozano, D Serrano, Y Senent, M Redrado, ... Journal for immunotherapy of cancer 9 (3), 2021 | 46 | 2021 |
| The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer E Martínez-Terroba, T Ezponda, C Bértolo, C Sainz, A Remírez, ... Laboratory Investigation 98 (12), 1562-1574, 2018 | 36 | 2018 |
| YES1: A novel therapeutic target and biomarker in cancer I Garmendia, E Redin, LM Montuenga, A Calvo Molecular Cancer Therapeutics 21 (9), 1371-1380, 2022 | 27 | 2022 |
| New syngeneic inflammatory‐related lung cancer metastatic model harboring double KRAS/WWOX alterations AM Bleau, J Freire, MJ Pajares, I Zudaire, I Anton, E Nistal‐Villán, ... International journal of cancer 135 (11), 2014 | 21 | 2014 |
| The SRC inhibitor dasatinib induces stem cell-like properties in head and neck cancer cells that are effectively counteracted by the mithralog EC-8042 F Hermida-Prado, MÁ Villaronga, R Granda-Díaz, N del-Río-Ibisate, ... Journal of Clinical Medicine 8 (8), 1157, 2019 | 17 | 2019 |
| The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma F Hermida-Prado, R Granda-Díaz, N del-Río-Ibisate, MÁ Villaronga, ... Cancers 11 (11), 1644, 2019 | 12 | 2019 |
| YES1 is a druggable oncogenic target in SCLC E Redin, EM Garrido-Martin, K Valencia, M Redrado, JL Solorzano, ... Journal of Thoracic Oncology 17 (12), 1387-1403, 2022 | 8 | 2022 |
| Acute influenza infection promotes lung tumor growth by reprogramming the tumor microenvironment I Garmendia, A Varthaman, S Marmier, M Angrini, I Matchoua, ... Cancer Immunology Research 11 (4), 530-545, 2023 | 1 | 2023 |
| Tumor-intrinsic nuclear β-catenin associates with an immune ignorance phenotype and a poorer prognosis in head and neck squamous cell carcinomas M Sánchez-Canteli, L Juesas, I Garmendia, M Otero-Rosales, A Calvo, ... International journal of molecular sciences 23 (19), 11559, 2022 | 1 | 2022 |
| Abstract LB-084: Dasatinib reduces tumor growth in xenograft models derived from human lung tumors with YES1 overexpression I Garmendia, C Bértolo, I Ferrer, MJ Pajares, D Ajona, L Paz-Ares, R Pio, ... Cancer Research 78 (13_Supplement), LB-084-LB-084, 2018 | 1 | 2018 |
| Abstract LB-117: Dasatinib for the treatment of patients with non-small cell lung cancer harboring YES1 amplification I Garmendia, J Agorreta, MJ Pajares, D Ajona, D Alameda, C Behrens, ... Cancer Research 77 (13_Supplement), LB-117-LB-117, 2017 | 1 | 2017 |
| MA17. 10 YES1 Kinase is a New Therapeutic Target in Non-small Cell Lung Cancer J Agorreta, I Garmendia, M Pajares, D Ajona, D Alameda, C Behrens, ... Journal of Thoracic Oncology 12 (1), S446-S447, 2017 | 1 | 2017 |
| FP03. 04 Dasatinib Improves the Antitumor Activity of Anti-PD-1 in NSCLC Models by Inhibiting Treg Conversion and Proliferation E Redin, I Garmendia, T Lozano, D Serrano, Y Senent, M Redrado, ... Journal of Thoracic Oncology 16 (10), S949, 2021 | | 2021 |
